Fulgent Genetics, Inc.

NASDAQ:FLGT

Medical - Diagnostics & Research

Healthcare
$25.13 +1.89%

+$0.33 today

Market cap
$702.11M
Beta
0.92
P/E (TTM)
-7.5
EPS (TTM)
-$2.39
52W Low $13.46High $31.04

Volume 0.39M

Average 0.55M

FLGT Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Fulgent Genetics, Inc.NASDAQ: FLGT

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $24.83M (cash outflow) rose 108.6% year over year, ahead of the +78.1% change in trailing-twelve-month net income. Sequentially, it rose 5.0% from the prior quarter.

Context

  • Net income amounted to 19.1% of revenue in FY2025, up 3.6 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$52.32M (-15.1%) for the fiscal year ending Dec 2026, a slowdown from the +40.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$24.83M+5.0% QoQ
Last fiscal yearDec 2025
-$61.63M+40.6% YoY
LTMMar 2026
-$74.56M+78.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+108.6%-33.9%-142.6 pp
1 year+40.6%-15.1%-55.8 pp
3-year CAGR—-21.2%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(61.63M) USD
Year-over-year change
-40.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How FLGT compares with its peers on the latest reported figures

  • FLGT's LTM Mar 2026 net income of $74.56M is the 6th largest of the 8 companies compared; the peer median is $106.36M.
  • Its year-over-year change of +78.1% is the 2nd highest of 7, against a peer median of -5.2%.
  • Net income amounts to 23.3% of revenue for FLGT, versus a peer median of 23.4%.
FLGT Competitors Peer median
Net Income for FLGT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$485.07M +21.6%-14.0%37.9%
MYGNMyriad Genetics, Inc.LTM Mar 2026$399.9M +294.4%+48.4%48.2%
NTRANatera, Inc.LTM Jun 2026$192.35M -24.0%-27.6%7.1%
WGSGeneDx Holdings Corp.LTM Jun 2026$106.36M -7664.5%-66.3%23.4%
PSNLPersonalis, Inc.LTM Mar 2026$95.55M +13.7%-10.5%148.1%
FLGTFulgent Genetics, Inc.LTM Mar 2026$74.56M +78.1%—23.3%
NEONeoGenomics, Inc.LTM Jun 2026$51.88M -50.1%-9.2%6.8%
BLLNBillionToOne, Inc.LTM Jun 2026$37.71M ——9.5%
FRNMFreenome, Inc. Common stock—— ———
Peer median (excluding FLGT) $106.36M-5.2%-12.2%23.4%

Competitors are the stored peer set for FLGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income506.24M141.92M(175.24M)(43.82M)(61.63M)
Depreciation & Amortization11M32.66M26.14M24.93M24.12M
Deferred Income Tax(7.84M)831K7.61M(5.15M)(1.21M)
Stock-Based Compensation15.88M32.64M42.92M44.48M39.58M
Change in Working Capital(2.68M)2.01M2.84M(7.24M)(117.63M)
Accounts Receivables42.3M68.64M2.39M(16.3M)(23.25M)
Inventory00000
Accounts Payables(12.21M)(25.34M)(6.9M)3.07M550K
Other Working Capital(32.77M)(41.29M)7.35M6M(94.93M)
Other Non-Cash Items15.97M43.46M122.73M7.86M15.14M
Operating Cash Flow538.58M253.52M27M21.06M(101.64M)
Capital Expenditures(23.84M)(18.78M)(22.21M)(40.32M)(22.57M)
Acquisitions (Net)(61.87M)(182.68M)(399K)03.78M
Purchases of Investments(730.49M)(432.98M)(491.91M)(472.42M)(80.84M)
Sales of Investments269.59M372.71M552.64M454.07M211.01M
Other Investing Activities31K412K775K313K5K
Investing Cash Flow(546.55M)(261.31M)38.9M(58.35M)111.37M
Debt Repayment(11K)(1.07M)(20M)(1.77M)(870K)
Common Stock Issued89.48M0001K
Common Stock Repurchased(4.16M)(76.11M)(27.79M)(3.12M)(13.92M)
Dividends Paid00000
Other Financing Activities96K31K3K51K0
Financing Cash Flow85.41M(77.14M)(47.79M)(4.85M)(14.79M)
Effect of Forex Changes34K(453K)(149K)(55K)105K
Net Change in Cash77.47M(85.39M)17.97M(42.19M)(4.95M)
Free Cash Flow514.73M234.75M4.8M(19.26M)(124.21M)

Fulgent Genetics, Inc.

NASDAQ:FLGT

Intrinsic Alpha fair value

Locked

Current Price

$25.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.